ReportsnReports adds — Non Alcoholic Fatty Liver Disease (NAFLD) Market research to its database.
Companies discussed in this research are Arisaph Pharmaceuticals, Inc., AstraZeneca Plc, Betagenon AB, Can-Fite BioPharma Ltd., Conatus Pharmaceuticals Inc., Corcept Therapeutics Incorporated, Daewoong Pharmaceutical Co., Ltd., Dimerix Bioscience Pty Ltd, Dr. Falk Pharma GmbH, DURECT Corporation, Galmed Pharmaceuticals Ltd., Gilead Sciences, Inc., Huons Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Novartis AG, Sancilio & Company, Inc., TaiwanJ Pharmaceuticals Co., Ltd., TCM Biotech International Corp, Tobira Therapeutics, Inc., Verva Pharmaceuticals Limited, Zafgen Inc. and Zydus Cadila Healthcare Limited.
Get discount on this research at http://www.reportsnreports.com/contacts/Discount.aspx?name=520863 .
The report provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Complete research report of 134 pages with TOC is available at http://www.reportsnreports.com/reports/520863-non-alcoholic-fatty-liver-disease-nafld-pipeline-review-h1-2016.html .
• The report provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD)
• The report reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics and enlists all their major and minor projects
• The report assesses Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD)
Reasons to buy
• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD)
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Name: Ritesh Tiwari
Email: Send Email
Address: UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune, Maharashtra 411013, India
Phone: +1888 391 54 41
Release ID: 109362